Massive hypertriglyceridemia associated with paclitaxel; a case report
- PMID: 35782104
- PMCID: PMC9241137
- DOI: 10.1016/j.gore.2022.101030
Massive hypertriglyceridemia associated with paclitaxel; a case report
Abstract
This report describes a patient who developed massive hypertriglyceridemia (12,488 mg/dL or 141 mmol/L) during paclitaxel and carboplatin adjuvant chemotherapy for high grade serous fallopian tube carcinoma. Paclitaxel was thought to be the causative agent and she had normal triglyceride levels following a change to carboplatin and gemcitabine. To our knowledge, this is the highest reported triglyceride level associated with paclitaxel. Measurement of serum lipids should be considered in individuals receiving taxane chemotherapy, especially in those with type 2 diabetes mellitus or a history of dyslipidemia.
Keywords: Fallopian tube carcinoma; Hypertriglyceridemia; Paclitaxel.
Crown Copyright © 2022 Published by Elsevier Inc.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
References
-
- Stasenko M., Fillipova O., Tew W.P. Fallopian tube carcinoma. J. Oncol. Pract. 2019;15(7):375–382. - PubMed
-
- Stewart S.L., Wike J.M., Foster S.L., Michaud F. The incidence of primary fallopian tube cancer in the United States. Gynecol. Oncol. 2007;107(3):392–397. - PubMed
-
- Brunzell J.D. Hypertriglyceridemia. N. Engl. J. Med. 2007;357(10):1009–1017. - PubMed
-
- Watanabe A., Tanabe A., Maruoka R., Nakamura K., Hatta K., Ono Y.J., Terai Y., Ohmichi M. Fibrates protect against vascular endothelial dysfunction induced by paclitaxel and carboplatin chemotherapy for cancer patients: a pilot study. Int. J. Clin. Oncol. 2015;20(4):829–838. - PubMed
Publication types
LinkOut - more resources
Full Text Sources